Loading
DAHANCA 5 is the trial that made hypoxic sensitisation real in the clinic: nimorazole with radiotherapy improved control of head and neck cancer, and Denmark has used it as standard ever since.
DAHANCA 5 randomised 422 patients with carcinoma of the supraglottic larynx or pharynx to nimorazole or placebo during conventional radiotherapy. Five-year locoregional control was 49 percent with nimorazole and 33 percent with placebo, with a survival advantage in the pharynx subgroup and minimal added toxicity (Overgaard and colleagues, Radiotherapy and Oncology 1998). A later analysis showed the benefit was confined to tumours with a hypoxic gene signature, and a European confirmatory trial (EORTC 1219) followed.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
422 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Locoregional control at 5 yearsprimary | Nimorazole plus radiotherapy | 219 | 49% | - | - | - |
| Placebo plus radiotherapy | 203 | 33% |
Shares Radiosensitisers and the tag radiation-wave2.
Shares Tumour hypoxia: imaging and modification, Radiosensitisers.
Shares Tumour hypoxia, Head and neck squamous cell carcinoma.
Shares Tumour hypoxia, Tumour hypoxia: imaging and modification, Radiosensitisers.
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
Shares Radiosensitisers, Head and neck squamous cell carcinoma.